PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
26 sept. 2024 01h00 HE
|
PolTREG S.A.
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
19 sept. 2024 10h50 HE
|
Precede Biosciences, Inc.
Precede Biosciences Presents Data on Liquid Biopsy Comprehensive Epigenomic Profiling of MS Patients at ECTRIMS 2024
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
16 sept. 2024 01h00 HE
|
PolTREG S.A.
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to...
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
22 août 2024 07h00 HE
|
Abata
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
Multiple Sclerosis Market Set to Reach USD 33.57 Billion by 2032, Growing at a CAGR of 5.4% | Polaris Market Research (PMR)
19 août 2024 08h25 HE
|
Polaris Market Research & Consulting LLP
New York, USA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview: The multiple sclerosis market was estimated at USD 21.04 billion in 2023. The market valuation is expected to be USD 33.57 billion...
Autoinjectors Market Size to Hit USD 3.8 Billion Milestone by 2034 with 16.2% CAGR Growth | Exclusive Report by Transparency Market Research, Inc.
19 août 2024 07h25 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The autoinjectors market (自動注射器市場) value was US$ 1.0 Billion in 2022 and is anticipated to...
Tiziana Life Sciences Appoints New Chief Executive Officer
19 août 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline into Clinical Development
15 août 2024 07h00 HE
|
Abata
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement of its Treg Cell Therapy Pipeline
Medsenic reçoit l'intention de délivrer un brevet européen clé de l'OEB, précieux pour le développement thérapeutique du trioxyde d'arsenic dans la sclérose en plaques récurrente-rémittente.
14 août 2024 01h00 HE
|
BioSenic
INFORMATION PRIVILEGIEE Le médicament de Medsenic, le trioxyde d'arsenic, peut maintenant être étudié pour le traitement de la sclérose en plaques par des cycles répétés d'administration par de...
Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis
14 août 2024 01h00 HE
|
BioSenic
INSIDE INFORMATION Medsenic's experimental drug, arsenic trioxide, can now be investigated for the treatment of multiple sclerosis through repeated cycles of administration by multiple routes,...